Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer

To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were: chemotherapy-naïve, small-cell lung cancer (SCLC), good performance status (PS: 0–2), age⩽75 years, and adequate organ function. The patients' characteristic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, A, Fukuda, M, Soda, H, Nagashima, S, Takatani, H, Kuba, M, Nakamura, Y, Tsurutani, J, Kohno, S, Oka, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361403/
https://www.ncbi.nlm.nih.gov/pubmed/16622467
http://dx.doi.org/10.1038/sj.bjc.6603079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361403/
https://www.ncbi.nlm.nih.gov/pubmed/16622467
http://dx.doi.org/10.1038/sj.bjc.6603079

Ejemplares similares